Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 253-256 , July 2009

Influenza and meningococcal disease: Lessons for travellers and government from 2 epidemic diseases

  • Robert Booy

      Affiliations

    • The Children's Hospital at Westmead and The University of Sydney, New South Wales, Australia
    • Academic Unit of Child Health, Barts and The London Queen Mary's School of Medicine and Dentistry, UK
    • Corresponding Author InformationCorresponding author. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Disease, The Children's Hospital at Westmead and The University of Sydney, New South Wales, Locked Bag 4001, Westmead NSW 2145, Australia. Tel.: +61 (0)298451415; fax: +61 (0)298451418.
    • ,
  • Haitham El Bashir

      Affiliations

    • General and Adolescent Paediatric Unit, Institute of Child Health, University College London, UK
    • ,
  • Harunor Rashid

      Affiliations

    • Academic Unit of Child Health, Barts and The London Queen Mary's School of Medicine and Dentistry, UK
    • ,
  • Delane Shingadia

      Affiliations

    • Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street, London, UK
    • ,
  • Elizabeth Haworth

      Affiliations

    • Health Protection Agency South East, UK

Received 24 August 2008 ,Accepted 8 September 2008.

References 

  1. Rashid H, Haworth E, Shafi S, Memish ZA, Booy R. Pandemic influenza: mass gatherings and mass infection. Lancet Infect Dis. 2008;8:526–527
  2. Aguilera JF, Perrocheau A, Meffre C, Hahné S, W135 Working Group . Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8:761–767
  3. Chonghaile CN. Meningitis in Africa – tackling W135. Lancet. 2002;360:2054–2055
  4. Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet. 1989;2:260–263
  5. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarski EB, Palmer SR. Influenza A and meningococcal disease. Lancet. 1991;338:554–557
  6. Cartwright K. Meningococcal disease. Chichester, England: Wiley; 1995;
  7. Cauchemez S, Valleron AJ, Boëlle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature. 2008;452:750–754
  8. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282:417–420
  9. Hahné SJ, Gray SJ, Jean-François Aguilera, Crowcroft NS, Nichols T, Kaczmarski EB, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet. 2002;359:582–583
  10. Klaber R, Booy R, El Bashir H, Mifsud A, Taylor S. Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet. 2002;360:644
  11. El Bashir H, Haworth E, Zambon M, Shafi S, Zuckerman J, Booy R. Influenza among U.K. pilgrims to hajj, 2003. Emerg Infect Dis. 2004;10:1882–1883
  12. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173–184
  13. Rashid H, Booy R, Shafi S, Haworth E. Conjugate versus polysaccharide meningococcal vaccine. Lancet Infect Dis. 2008;8:215
  14. Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332:445–450
  15. Coen PG, Tully J, Stuart JM, Ashby D, Viner RM, Booy R. Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers?. Int J Epidemiol. 2006;35:330–336
  16. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58–S67
  17. Krizova P, Musilek M. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Cent Eur J Public Health. 1995;3:189–194
  18. Kriz P, Kriz B, Svandova E, Musilek M. Antimeningococcal herd immunity in the Czech Republic – influence of an emerging clone, Neisseria meningitidis ET-15/37. Epidemiol Infect. 1999;123:193–200
  19. Cardeñosa N, Domínguez A, Martínez A, Alvarez J, Panella H, Godoy P, et al. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine. Infection. 2003;31:392–397
  20. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA. 2001;285:177–181
  21. Karlen A. Plague's progress. London: Phoenix; 2001;

PII: S1477-8939(08)00123-3

doi: 10.1016/j.tmaid.2008.09.001

Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 253-256 , July 2009

Article Tools